DBL™ Pemetrexed (as disodium) powder for infusion

Riik: Uus-Meremaa

keel: inglise

Allikas: Medsafe (Medicines Safety Authority)

Toimeaine:

Pemetrexed disodium 562.43mg (as 2.5-hydrate, equivalent to pemetrexed 500 mg)

Saadav alates:

Pfizer New Zealand Limited

INN (Rahvusvaheline Nimetus):

Pemetrexed disodium 562.43 mg (as 2.5-hydrate, equivalent to pemetrexed 500 mg)

Annus:

500 mg

Ravimvorm:

Powder for infusion

Koostis:

Active: Pemetrexed disodium 562.43mg (as 2.5-hydrate, equivalent to pemetrexed 500 mg) Excipient: Hydrochloric acid Mannitol Sodium hydroxide

Ühikuid pakis:

Vial, glass, clear, Type I, with grey bromobutyl rubber closure, Al seal, flip off top, 50 mL, 1 dose unit

Klass:

Prescription

Retsepti tüüp:

Prescription

Valmistatud:

Chongqing Pharmaceutical Research Institute

Näidustused:

DBL™ Pemetrexed (as disodium) powder for infusion, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.

Toote kokkuvõte:

Package - Contents - Shelf Life: Vial, glass, clear, Type I, with grey bromobutyl rubber closure, Al seal, flip off top, 50 mL - 1 dose units - 36 months from date of manufacture stored at or below 25°C

Loa andmise kuupäev:

2012-01-06

Toote omadused

[Medsafe: New Zealand Medicines and Medical Devices Safety Authority]
[/index.asp]
MEDSAFE [/index.asp]
-------------------------
NEW ZEALAND MEDICINES AND MEDICAL DEVICES SAFETY AUTHORITY
[/index.asp]
Search: *
Medicines [/Medicines/medicines-landing.asp] *
Medicine Information [/Medicines/medicine-information.asp] *
Approval Process [/Medicines/regulatory-approval-process.asp] *
Regulatory Guidance [/Medicines/regulatory-landing.asp] *
Clinical Trials [/Medicines/clinical-trials.asp] *
Classification [/profs/class/clascon.asp] *
Manufacturing [/Medicines/manufacturing.asp] * Devices [/devices/devices-landing.asp] *
WAND [/regulatory/DevicesNew/3WAND.asp] *
Regulatory Guidance [/regulatory/DevicesNew/industry.asp] *
Surgical Mesh [/devices/Surgical%20Mesh/Landing.asp] *
Safety Information [/regulatory/DevicesNew/safety.asp] *
Product Recalls [/hot/ProductRecallInformation/ProductRecallHome.asp] *
Device Information [/devices/education-and-information.asp] * Safety [/safety/safety-landing.asp] *
Safety Information [/safety/education-and-information.asp] *
Product Recalls [/hot/ProductRecallInformation/ProductRecallHome.asp] *
Safety Communications [/safety/alerts.asp] *
Adverse Reaction Reporting [/safety/ADR-reporting.asp] * Compliance [/compliance/compliance-landing.asp] *
Unapproved Medicines [/profs/RIss/unapp.asp] *
Recalls [/hot/ProductRecallInformation/ProductRecallHome.asp] *
Marketing [/compliance/advertising.asp] *
Importing Medicines [/compliance/importing-medicines.asp] *
DG Statements [/publications/dg-statements.asp] *
Manufacturing [/Medicines/manufacturing.asp] * Publications [/publications/publications-landing.asp] *
Media [/hot/MediaContents.asp] *
Prescriber Update [/publications/prescriber-update.asp] *
OIA Releases [/publications/oia.asp] * Consultations [/consultations/consultations-landing.asp] *
Current [/consultations/current.asp] *
Closed [/consultations/closed.asp] *
Outcomes [/consultations/outcome.asp] * Committees [/committees/committees-landing.asp] *
Medicines Classification [/comm